Yamada Y, et al. - In this open-label, phase 3, randomized controlled trial, researchers from Japan assessed the superiority of docetaxel plus cisplatin and S-1 vs cisplatin and S-1 in chemotherapy-naive patients with advanced gastric cancer. Seven hundred forty-one patients were randomly assigned to receive docetaxel plus cisplatin and S-1 (n=370) or cisplatin and S-1 (n=371) between April 3, 2012 and March 18, 2016. In chemotherapy-naive Japanese patients with advanced gastric cancer, the addition of docetaxel to cisplatin and S-1 did not improve overall survival. Cisplatin and S-1 remain the standard first-line chemotherapy. Neutropenia, leukopenia, and anorexia were the most common grade 3 or worse adverse events.